MTIX Micro Therapeutics (MM)

Micro Therapeutics Receives $3.7 Million Payment IRVINE, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Micro Therapeutics, Inc. (MTI) (NASDAQ:MTIX) today said that it has received a $3.7 million payment resulting from the acquisition of certain assets of Genyx Medical, Inc., a company in which MTI held a minority equity interest, by C. R. Bard Inc. (NYSE:BCR). Genyx, a privately held company based in Aliso Viejo, CA, licensed MTI's proprietary liquid embolic technology for certain non-vascular applications in 1997. Genyx recently announced that it had received FDA approval for URYX(R), an injectable tissue bulking agent for the treatment of stress urinary incontinence that is based on the technology licensed from MTI. About Micro Therapeutics, Inc. MTI develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of vascular disorders. The company's primary focus is on catheter based technologies and products for the interventional neuroradiology market. MTI's products include the Sapphire(R) and NXT lines of embolic coils, the ONYX(R) liquid embolic system, and a broad line of micro catheters, guidewires, and occlusion balloons that are utilized in the treatment of cerebral vascular disorders. DATASOURCE: Micro Therapeutics, Inc. CONTACT: Thomas C. Wilder of Micro Therapeutics, Inc., +1-949-837-3700; or Rob Whetstone or Robert Jaffe, both of PondelWilkinson Inc., +1-310-279-5963, for Micro Therapeutics, Inc.

Copyright